https://www.selleckchem.com/products/AZD0530.html
Patients with relapsed/refractory AL amyloidosis (RRAL) have poor prognosis, but emerging data shows promising results with the use daratumumab. We evaluated daratumumab treatment in RRAL in real-world setting. A retrospective multisite study of RRAL patients treated with daratumumab alone and in combinations. Forty-nine patients, diagnosed between 1.1.2008 and 1.2.2018 were included; 27% also had multiple myeloma (MM). Revised Mayo score was≥3 in 67%. Hematologic overall response rate was 81%, 64% achieved very good partial response (V